FDA Brief

Warning letters Drugs

FDA warning letter to

123Herbals

High riskIssued Nov 13, 2025Posted Nov 18, 2025Center for Drug Evaluation and Research (CDER)

FDA warned 123Herbals that SILINTAN and other herbal products are unapproved drugs, and SILINTAN contains hidden meloxicam.

What happened

FDA reviewed 123Herbals' website from July to November 2025 and found six products sold with claims to treat conditions such as gout, arthritis, bronchitis, kidney problems, diabetes, and gastric pain. FDA also obtained and tested a sample of SILINTAN and found meloxicam, an NSAID, not declared on the label. FDA cited the products as unapproved new drugs and SILINTAN as misbranded because its label omits the hidden drug.

What FDA found

  1. The website claims the six products treat diseases or body functions, so they are intended as drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128
  2. The six products are new drugs because they are not generally recognized as safe and effective for their claimed uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  3. No FDA-approved application is in effect for the six products, so selling them violates the unapproved-drug provision.

    FD&C Act section 505(a), 21 U.S.C. 355(a); section 301(d), 21 U.S.C. 331(d)
  4. SILINTAN contains meloxicam, an NSAID, but the label does not declare it, so the labeling is false or misleading.

    FD&C Act section 502(a), 21 U.S.C. 352(a); section 201(n), 21 U.S.C. 321(n)

What FDA wants

FDA asks 123Herbals to notify it in writing within 15 working days of the specific steps taken to correct the violations, with an explanation and supporting documents. If correction cannot be completed in that time, the company must state the reason and the time needed.

Who should pay attention

  • consumers who bought SILINTAN or similar herbal pain products
  • online sellers of imported herbal remedies
  • quality teams checking product labels and disease-treatment claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk